Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENCHANT: Enfortumab vedotin in advanced urachal cancer after chemotherapy failure
KCT0010025Phase 2Recruiting
- Sponsor
- Astellas Pharma
- Start
- Apr 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enfortumab vedotin in urachal cancer, sponsored by Astellas Pharma. Started Apr 2025; status: recruiting.
02
Drugs
enfortumab vedotin
03
Conditions
urachal cancer
Beyond the preview
Go deeper on KCT0010025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010025.